Reconstructing the household transmission of influenza in the suburbs of Tokyo based on clinical cases.

Household transmission Infectious period Influenza Mathematical model Secondary attack ratio Stochastic simulation

Journal

Theoretical biology & medical modelling
ISSN: 1742-4682
Titre abrégé: Theor Biol Med Model
Pays: England
ID NLM: 101224383

Informations de publication

Date de publication:
10 02 2021
Historique:
received: 25 06 2020
accepted: 30 01 2021
entrez: 11 2 2021
pubmed: 12 2 2021
medline: 28 4 2021
Statut: epublish

Résumé

Influenza is a public health issue that needs to be addressed strategically. The assessment of detailed infectious profiles is an important part of this effort. Household transmission data play a key role in estimating such profiles. We used diagnostic and questionnaire-based data on influenza patients at a Japanese clinic to estimate the detailed infectious period (as well as incubation period, symptomatic and infectious periods, and extended infectious period after recovery) and the secondary attack ratio (SAR) of influenza for households of various sizes based on a modified Cauchemez-type model. The data were from enrolled patients with confirmed influenza who were treated at the Hirotsu Clinic (Kawasaki, Japan) with a neuraminidase inhibitor (NAI) during six northern hemisphere influenza seasons between 2010 and 2016. A total of 2342 outpatients, representing 1807 households, were included. For influenza type A, the average incubation period was 1.43 days (95% probability interval, 0.03-5.32 days). The estimated average symptomatic and infective period was 1.76 days (0.33-4.62 days); the extended infective period after recovery was 0.25 days. The estimated SAR rose from 20 to 32% as household size increased from 3 to 5. For influenza type B, the average incubation period, average symptomatic and infective period, and extended infective period were estimated as 1.66 days (0.21-4.61), 2.62 days (0.54-5.75) and 1.00 days, respectively. The SAR increased from 12 to 21% as household size increased from 3 to 5. All estimated periods of influenza type B were longer than the corresponding periods for type A. However, the SAR for type B was less than that for type A. These results may reflect Japanese demographics and treatment policy. Understanding the infectious profiles of influenza is necessary for assessing public health measures.

Sections du résumé

BACKGROUND
Influenza is a public health issue that needs to be addressed strategically. The assessment of detailed infectious profiles is an important part of this effort. Household transmission data play a key role in estimating such profiles. We used diagnostic and questionnaire-based data on influenza patients at a Japanese clinic to estimate the detailed infectious period (as well as incubation period, symptomatic and infectious periods, and extended infectious period after recovery) and the secondary attack ratio (SAR) of influenza for households of various sizes based on a modified Cauchemez-type model.
RESULTS
The data were from enrolled patients with confirmed influenza who were treated at the Hirotsu Clinic (Kawasaki, Japan) with a neuraminidase inhibitor (NAI) during six northern hemisphere influenza seasons between 2010 and 2016. A total of 2342 outpatients, representing 1807 households, were included. For influenza type A, the average incubation period was 1.43 days (95% probability interval, 0.03-5.32 days). The estimated average symptomatic and infective period was 1.76 days (0.33-4.62 days); the extended infective period after recovery was 0.25 days. The estimated SAR rose from 20 to 32% as household size increased from 3 to 5. For influenza type B, the average incubation period, average symptomatic and infective period, and extended infective period were estimated as 1.66 days (0.21-4.61), 2.62 days (0.54-5.75) and 1.00 days, respectively. The SAR increased from 12 to 21% as household size increased from 3 to 5.
CONCLUSION
All estimated periods of influenza type B were longer than the corresponding periods for type A. However, the SAR for type B was less than that for type A. These results may reflect Japanese demographics and treatment policy. Understanding the infectious profiles of influenza is necessary for assessing public health measures.

Identifiants

pubmed: 33568160
doi: 10.1186/s12976-021-00138-x
pii: 10.1186/s12976-021-00138-x
pmc: PMC7873673
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7

Références

Stat Med. 2004 Nov 30;23(22):3469-87
pubmed: 15505892
Euro Surveill. 2011 Jan 20;16(3):
pubmed: 21262182
Influenza Other Respir Viruses. 2019 Mar;13(2):123-132
pubmed: 29989680
Biometrics. 1982 Mar;38(1):115-26
pubmed: 7082755
Arch Intern Med. 2002 Sep 9;162(16):1842-8
pubmed: 12196082
Prev Med Rep. 2016 Dec 06;5:86-91
pubmed: 27981021
Hum Biol. 1952 Sep;24(3):201-33
pubmed: 12990130
J Epidemiol Community Health. 2016 Feb;70(2):162-7
pubmed: 26424846
J Int Med Res. 2011;39(2):619-28
pubmed: 21672367
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2015-20
pubmed: 16461461
Heliyon. 2020 Feb 14;6(2):e03385
pubmed: 32090182
Science. 2005 Aug 12;309(5737):1083-7
pubmed: 16079251
Nature. 2005 Sep 8;437(7056):209-14
pubmed: 16079797
Am J Epidemiol. 2006 Nov 15;164(10):936-44
pubmed: 16968863
Vaccine. 2018 May 31;36(23):3199-3207
pubmed: 29716771
BMC Public Health. 2011 Feb 04;11:79
pubmed: 21291570
PLoS Med. 2008 Mar 25;5(3):e74
pubmed: 18366252

Auteurs

Masaya M Saito (MM)

University of Nagasaki Siebold, Nagasaki, Japan. saitohm@sun.ac.jp.
The Institute of Statistical Mathematics, Tokyo, Japan. saitohm@sun.ac.jp.

Nobuo Hirotsu (N)

Hirotsu Clinic, Kawasaki, Japan.

Hiroka Hamada (H)

The Institute of Statistical Mathematics, Tokyo, Japan.

Mio Takei (M)

The Institute of Statistical Mathematics, Tokyo, Japan.

Keisuke Honda (K)

The Institute of Statistical Mathematics, Tokyo, Japan.

Takamichi Baba (T)

Shionogi & Co., Ltd., Osaka, Japan.

Takahiro Hasegawa (T)

Shionogi & Co., Ltd., Osaka, Japan.

Yoshitake Kitanishi (Y)

Shionogi & Co., Ltd., Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH